• Explore /
  • Poster
  • / Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.

Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.

Abstract Poster

Authors

null

Prajwal Boddu

The University of Texas MD Anderson Cancer Center, Houston, TX

Prajwal Boddu , Gautam Borthakur , Kiran Naqvi , William G. Wierda , Prithviraj Bose , Elias Jabbour , Zeev Estrov , Jan Andreas Burger , Yesid Alvarado , APRIL Deshmukh , Ami Patel , Antonio Cavazos , Lina Han , Hagop M. Kantarjian , Michael Andreeff , Marina Konopleva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02652871

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7026)

DOI

10.1200/JCO.2018.36.15_suppl.7026

Abstract #

7026

Poster Bd #

86

Abstract Disclosures

Similar Posters

First Author: Kim Schellekens

First Author: Pierre Peterlin

First Author: Daniel J. DeAngelo

First Author: Peter D. Cole